ES2524645B1 - Oral formulation for the treatment of cardiovascular diseases - Google Patents

Oral formulation for the treatment of cardiovascular diseases Download PDF

Info

Publication number
ES2524645B1
ES2524645B1 ES201330841A ES201330841A ES2524645B1 ES 2524645 B1 ES2524645 B1 ES 2524645B1 ES 201330841 A ES201330841 A ES 201330841A ES 201330841 A ES201330841 A ES 201330841A ES 2524645 B1 ES2524645 B1 ES 2524645B1
Authority
ES
Spain
Prior art keywords
treatment
cardiovascular diseases
oral formulation
statin
acetylsalicylic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES201330841A
Other languages
Spanish (es)
Other versions
ES2524645A1 (en
Inventor
Pablo MARTÍN SANZ
Javier URBANO HURTADO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ferrer Internacional SA
Fundacion Centro Nacional de Investigaciones Cardiovasculares Carlos III
Original Assignee
Ferrer Internacional SA
Fundacion Centro Nacional de Investigaciones Cardiovasculares Carlos III
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferrer Internacional SA, Fundacion Centro Nacional de Investigaciones Cardiovasculares Carlos III filed Critical Ferrer Internacional SA
Priority to ES201330841A priority Critical patent/ES2524645B1/en
Publication of ES2524645A1 publication Critical patent/ES2524645A1/en
Application granted granted Critical
Publication of ES2524645B1 publication Critical patent/ES2524645B1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere al uso de una composición farmacéutica que incluye un inhibidor de la HMG-CoA reductasa, en particular, una estatina y ácido acetilsalicílico de manera que se minimiza la interacción del ácido acetilsalicílico con la estatina, para la prevención o el tratamiento de enfermedades cardiovasculares.The present invention relates to the use of a pharmaceutical composition that includes an HMG-CoA reductase inhibitor, in particular, a statin and acetylsalicylic acid so that the interaction of acetylsalicylic acid with the statin is minimized, for the prevention or treatment of cardiovascular diseases.

Description

imagen1image 1

imagen2image2

imagen3image3

imagen4image4

imagen5image5

imagen6image6

imagen7image7

imagen8image8

imagen9image9

imagen10image10

imagen11image11

imagen12image12

imagen13image13

imagen14image14

imagen15image15

imagen16image16

imagen17image17

imagen18image18

imagen19image19

imagen20image20

imagen21image21

imagen22image22

imagen23image23

imagen24image24

imagen25image25

imagen26image26

imagen27image27

Claims (1)

imagen1image 1 imagen2image2 imagen3image3 imagen4image4
ES201330841A 2013-06-06 2013-06-06 Oral formulation for the treatment of cardiovascular diseases Active ES2524645B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
ES201330841A ES2524645B1 (en) 2013-06-06 2013-06-06 Oral formulation for the treatment of cardiovascular diseases

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES201330841A ES2524645B1 (en) 2013-06-06 2013-06-06 Oral formulation for the treatment of cardiovascular diseases

Publications (2)

Publication Number Publication Date
ES2524645A1 ES2524645A1 (en) 2014-12-10
ES2524645B1 true ES2524645B1 (en) 2015-12-02

Family

ID=52004086

Family Applications (1)

Application Number Title Priority Date Filing Date
ES201330841A Active ES2524645B1 (en) 2013-06-06 2013-06-06 Oral formulation for the treatment of cardiovascular diseases

Country Status (1)

Country Link
ES (1) ES2524645B1 (en)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6669955B2 (en) * 2001-08-28 2003-12-30 Longwood Pharmaceutical Research, Inc. Combination dosage form containing individual dosage units of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
TR201005325A2 (en) * 2010-06-30 2012-01-23 Bi̇lgi̇ç Mahmut Pharmaceutical formulations containing atorvastatin and aspirin
KR20120068277A (en) * 2010-12-17 2012-06-27 한미사이언스 주식회사 PHARMACEUTICAL COMPOSITE FORMULATION COMPRISING HMG-CoA REDUCTASE INHIBITOR AND ASPIRIN
KR101298788B1 (en) * 2011-03-15 2013-08-22 보령제약 주식회사 A combined formulation with improved stability

Also Published As

Publication number Publication date
ES2524645A1 (en) 2014-12-10

Similar Documents

Publication Publication Date Title
CL2023000767A1 (en) Methods to reduce the risk of cardiovascular events in a subject.
NI202100009A (en) METHODS TO REDUCE THE NEED FOR REVASCU
ES2487271T3 (en) DPP-IV inhibitor solid dosage formulations
SV2018005621A (en) INHIBITOR OF MUTED DEHYDROGENASE ISOCITRATE IDH1 R132H
ES2421956B1 (en) NEW CRYSTAL FORM OF SITAGLIPTINA SULFATE
CL2015002253A1 (en) Pharmaceutical compositions for the treatment of helicobacter pylori.
ECSP15050273A (en) ORAL FORMULATION FOR THE TREATMENT OF CARDIOVASCULAR DISEASES
CL2014000606A1 (en) Pharmaceutical combination comprising the compound 2- {2 - [(2s) -2-methyl-2,3-dihydro-1h-indol-1-yl] -2-oxoethyl} -6- (morpholin-4-yl) pyrimidin -4- (3h) -one and at least one inhibitor of the mapk pathway; pharmaceutical composition; pharmaceutical kit; its use in the treatment of cancer.
ES2598753T3 (en) Pharmaceutical composition for the treatment of calcified tendinitis and / or calcified bursitis
UY34455A (en) COMPLEX ORAL FORMULATION THAT INCLUDES OMEGA 3 FATTY ACID AND INHIBITOR OF THE HMG-COA REDUCED WITH IMPROVED STABILITY
CL2016000179A1 (en) Combination formulation containing extended-release metformin and immediate-release hmg-coa reductase inhibitor.
CO2019007671A2 (en) A pharmaceutical composition comprising an oxazine derivative and its use in the treatment or prevention of Alzheimer's disease
ES2524645B1 (en) Oral formulation for the treatment of cardiovascular diseases
UY35445A (en) LIPOEQUILIBRATED LONG CHAIN TESTOSTERONE ESTERS FOR ORAL ADMINISTRATION
ES2422877B1 (en) COMBINATION AND COMPOSITION FOR OBESITY TREATMENT
CO7170180A2 (en) Injectable pharmaceutical composition of dexketoprofen and tramadol
ES2536842T3 (en) Pharmaceutical composition for cancer treatment
ES2643369T3 (en) Modified-release oral pharmaceutical formulation containing gliclazide
ES2533758B1 (en) Composition comprising albumin for use in the treatment of decompensated cirrhosis
UA111358C2 (en) Drug in form of tablets or hard capsules exhibiting sedative and hypnotic effects
TH126521A (en) A pharmaceutical formulation in a two-layer tablet formulation that includes: HMG-COA Reductase Inhibitor and Urbesar Tan

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 2524645

Country of ref document: ES

Kind code of ref document: B1

Effective date: 20151202